Navigation Links
DATATRAK Signs Five-Year Registry Study
Date:1/12/2010

CLEVELAND, Jan. 12 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a new biopharmaceutical client with the award of a registry study for monitoring post surgical patients requiring chronic hemodialysis. This five-year study will track patients from several previous clinical trials seeking to improve the outcomes and reduce the suffering of dialysis patients with end-stage renal disease.

"DATATRAK is pleased to welcome a new biopharmaceutical client to the eClinical platform," said Laurence Birch, DATATRAK's Chairman of the Board. "This latest contract award is another new registry study running on DATATRAK eClinical™ and exemplifies industry recognition of DATATRAK eClinical's multifaceted capabilities."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
2. PFC Pharma Joins DATATRAKs CRO Connect Program
3. DATATRAK Signs 6 Year Study with New Device Client
4. DATATRAK to Present at 2009 SCDM Annual Conference
5. DATATRAK eClinical(TM) Supports Multifaceted Studies
6. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
7. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
8. DATATRAK International Reports First Quarter Results for 2008
9. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
10. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
11. AMICAS, Inc. Signs Merger Agreement with Thoma Bravo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 The global ... 16.0 billion by 2025, according to a new study ... chronic diseases is anticipated to be responsible for the ... widens the scope for growth during the forecast period. ... which is highly susceptible to chronic diseases, is presumed ...
(Date:3/27/2017)... , March 27, 2017 ... as the NASDAQ Composite closed the trading session up ... and the S&P 500 was down 0.08%. US markets ... sectors finishing the day in green. Pre-market today, Stock-Callers.com ... Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), ...
(Date:3/27/2017)... 2017  iCAD (Nasdaq: ICAD), an industry-leading provider ... therapy for the early identification and treatment of ... Premarket Approval (PMA) from the U.S. Food and ... first-of-its-kind, concurrent-read computer aided detection solution for digital ... available on the PowerLook® Breast Health Solutions platform.  ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... long time,” she said. , She thinks the coming week is going to be a ... would have to help my students.” , The award will allow the 4th grade teacher ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates and supports FNCC’s ... added 10 new sales professionals over the past 6 months and is continuing to ... hires over the course of 2017. , “This new office is a direct ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently ... and require expert user knowledge. In a live webinar on April 11th and ... yet highly accurate, determination of sodium. , It has long been known that ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
Breaking Medicine News(10 mins):